ACTRN12612001241820
Not yet recruiting
未知
A pilot study on the effects of intermittent and graded exercise compared to no exercise for optimising health and reducing symptoms in Chronic Fatigue Syndrome (CFS)patients.
Suzanne Broadbent0 sites60 target enrollmentNovember 23, 2012
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Chronic Fatigue Syndrome
- Sponsor
- Suzanne Broadbent
- Enrollment
- 60
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Medical diagnosis of Chronic Fatigue Syndrome: persistent and disabling, and/or recurring, fatigue lasting for more than 6 months, that does not result from physical exertion and that is not alleviated by rest. Other symptoms include muscle weakness and pain, ongoing medical symptoms such as swollen lymph nodes and fever, poor sleep, poor concentration and reduced quality of life.
Exclusion Criteria
- •Diagnosed cardiac and/or respiratory disease; joint or muscle condition/disease other than CFS, that is contraindicated for exercise; any mental health condition that may affect exercise participation or safety of participant and researchers.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
Comaparison of cisatracurium muscle relaxant administered via two different moethods during surgical procedures under general anaesthesiaHealth Condition 1: O- Medical and SurgicalCTRI/2021/01/030232Department of Anaesthesiology60
Active, not recruiting
Not Applicable
A clinical trial investigating OSI-906 in patients with cancer of thesurface of the ovary and other solid tumorsRecurrent Epithelial Ovarian Cancer and Other Solid TumorsMedDRA version: 14.1Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2009-010319-34-ITASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.199
Active, not recruiting
Phase 1
A clinical trial investigating OSI-906 in patients with cancer of the surface of the ovary and other solid tumorsRecurrent Epithelial Ovarian Cancer and Other Solid TumorsMedDRA version: 14.1 Level: LLT Classification code 10049280 Term: Solid tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10066697 Term: Ovarian cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2009-010319-34-GBAstellas Pharma Global Development, Inc.210
Active, not recruiting
Not Applicable
A clinical trial investigating OSI-906 in patients with cancer of the surface of the ovary and other solid tumorsEUCTR2009-010319-34-PLAstellas Pharma Global Development, Inc.199
Active, not recruiting
Not Applicable
A clinical trial investigating OSI-906 in patients with cancer of the surface of the ovary and other solid tumorsRecurrent Epithelial Ovarian Cancer and Other Solid TumorsMedDRA version: 14.1Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2009-010319-34-CZAstellas Pharma Global Development, Inc.199